NASDAQ · Biotechnology

Alkermes plc (ALKS) Stock

$43.63 -1.24% NASDAQ: ALKS Healthcare

Valuation

MetricValue
Price$43.63
Market Cap$7.32B
P/E Ratio103.60
P/B Ratio3.85
P/S Ratio4.20
EPS (TTM)$1.43
52-Week High$55.67
52-Week Low$27.00
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE3.72%
ROA1.51%
ROCE3.14%
Gross Margin17.21%
Operating Margin17.21%
Net Margin3.97%
Debt/Equity0.87
Current Ratio3.55

Annual Financials (USD)

Metric20212022202320242025
Revenue$1.2B$1.1B$1.7B$1.6B$1.5B
Operating Profit$98.0M$-6.0M$414.0M$421.0M$254.0M
Net Profit$-48.0M$-158.0M$356.0M$367.0M$242.0M
EPS$-0.30$-0.97$2.10$2.17$1.43
Op Margin8.3%-0.6%24.9%27.0%17.2%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$2.0B$2.0B$2.1B$2.1B$2.5B
Total Liabilities$912.0M$920.0M$934.0M$591.0M$711.0M
Cash$338.0M$292.0M$457.0M$291.0M$1.1B
Borrowings$416.0M$379.0M$372.0M$76.0M$70.0M

Latest News

Alkermes to Report Second Quarter Financial Results on July 28, 2026 Business Wire · Jul 14, 2026 American Express, Biogen upgraded: Wall Street's top analyst calls The Fly · Jul 13, 2026 Alkermes Public's Alixorexton Demonstrates Durable Efficacy in Narcolepsy Patients MT Newswires · Jul 13, 2026 Alkermes’ Alixorexton Demonstrated Sustained Improvement in Wakefulness in Adults With Narcolepsy Type 1 and Type 2 in Long-Term Extension Study Interim Analysis Business Wire · Jul 13, 2026 Arcturus Therapeutics (ARCT) Stock Jumps 5.7%: Will It Continue to Soar? Zacks · Jul 3, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$102.0M$21.0M$401.0M$439.0M$521.0M
Investing Cash Flow$-95.0M$-103.0M$5.0M$-145.0M$255.0M
Financing Cash Flow$-17.0M$-18.0M$-303.0M$-230.0M$-31.0M
Net Cash Flow$65.0M$-45.0M$165.0M$-166.0M$829.0M
Free Cash Flow$73.0M$-17.0M$353.0M$406.0M$480.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-1.27
EV / EBITDA36.99
FCF Yield3.16%
Quick Ratio1.85
Interest Coverage1.98
Return 1Y48.70%
Return 3Y42.20%
Return 5Y28.63%

Ownership

Insiders Held1.43%
Institutions Held110.67%
Institutions Float Held112.27%
Institutional HolderSharesReport Date
Blackrock Inc.28,314,4102026-03-31
Baker Bros. Advisors, LP10,012,2672026-03-31
Vanguard Portfolio Management LLC9,511,1122026-03-31
State Street Corporation9,465,2862026-03-31
Vanguard Capital Management LLC7,427,3972026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ACADACADIA Pharmaceuticals Inc. $19.73 -2.86% 8.87 $3.40B 0.00%
AXSMAxsome Therapeutics, Inc. $145.04 -7.07% -49.17 $7.60B 0.00%
JAZZJazz Pharmaceuticals plc $214.00 -0.30% 15.33 $13.89B 0.00%
NBIXNeurocrine Biosciences, Inc. $142.70 -0.41% 20.05 $14.51B 0.00%
SUPNSupernus Pharmaceuticals, Inc. $40.70 -3.26% -22.06 $2.37B 0.00%

About Alkermes plc

Alkermes plc is led by CEO Richard F. Pops, employs 2,050 people, headquartered in Dublin, IE, publicly traded since 1991.

Alkermes plc (ALKS) stock trades at $43.63 with a market capitalization of $7.32B. The stock is valued at a price-to-earnings (P/E) ratio of 103.60, price-to-book of 3.85, price-to-sales of 4.20. Over the past 52 weeks the stock has ranged between $27.00 and $55.67, and currently trades 21.6% below its 52-week high.

On profitability, Alkermes plc generates a return on equity (ROE) of 3.72%, return on capital employed of 3.14%, an operating margin of 17.21%, a net profit margin of 3.97%.

Alkermes plc by the numbers, 2016–2025

Between 2016 and 2025 Alkermes plc reported revenue of $746.0M rising to $1.5B, a change of +97.9% across 10 years. Compounded, revenue has grown 7.3% a year over five years, 9.9% over three, -5.3% over the last twelve months. Net profit rose to $242.0M.

Operating margin went from -28.0% in 2016 to 17.2% in 2025, a gain of 45.2 percentage points. The most recent net margin is 3.97%. On a trailing twelve-month basis to Jun '26, revenue is $1.7B and net profit $67.0M.

Borrowings fell from $284.0M to $70.0M, cash from operations was $521.0M in the latest year, positive in 9 of the last 10.

Return on equity has averaged 9.7% over five years, and was 13.3% in the most recent year.

The share price itself has compounded at —% a year over five years, —% over three, —% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Alkermes plc (ALKS) — frequently asked questions

What is Alkermes plc (ALKS) stock price today?

Alkermes plc (ALKS) is currently trading at $43.63, down 1.24% today.

What is ALKS P/E ratio?

Alkermes plc's P/E ratio is 103.60. This is above the typical market average of roughly 18-22x. A high P/E often reflects higher expected earnings growth, a temporary dip in earnings, or both.

What is ALKS return on equity (ROE)?

Alkermes plc's return on equity (ROE) is 3.72%. ROE measures net income relative to shareholders' equity. This is below the typical market range of roughly 12-15%.

What is Alkermes plc's market cap?

Alkermes plc has a market capitalization of $7.32B.

Does ALKS pay a dividend?

Alkermes plc is not currently showing a dividend yield in our data, which means no recent cash dividend was recorded for it.

How much debt does ALKS carry?

Alkermes plc has a debt-to-equity ratio of 0.87. That compares total borrowings with shareholders' equity: a figure under 1 means equity exceeds debt.

What is ALKS's profit margin?

Alkermes plc reports a net profit margin of 3.97% — the share of revenue left after every cost, including tax and interest.

What sector is ALKS in?

Alkermes plc is classified under Healthcare, in the Biotechnology industry. Ratios are most informative compared with other companies in the same industry rather than across the whole market.

Which exchange is ALKS listed on?

Alkermes plc trades on NASDAQ under the ticker ALKS.

What is ALKS's 52-week range?

Over the last year Alkermes plc has traded between $27.00 and $55.67.

Related Healthcare Stocks

LLY Eli Lilly and Company $1273.46 -2.54% JNJ Johnson & Johnson $263.81 -1.42% ABBV AbbVie Inc. $285.64 +0.16% UNH UnitedHealth Group Incorporated Common Stock (DE) $418.09 -1.62% MRK Merck & Company, Inc. Common Stock (new) $145.27 -1.34% NVS Novartis AG $151.12 -3.30% AZN AstraZeneca PLC $171.49 -0.63% TMO Thermo Fisher Scientific Inc $673.82 -0.40% AMGN Amgen Inc. $439.26 -1.79% GILD Gilead Sciences, Inc. $156.04 -0.73% ABT Abbott Laboratories $103.70 +1.16% NVO Novo Nordisk A/S $39.05 -0.96%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens ALKS currently matches

On the figures above, Alkermes plc passes the filters for 6 of our ready-made screens, among them High PE Stocks, Stocks Under $100, Stocks Under $50. Appearing on a screen means the numbers meet its filters today and nothing more; the list is rebuilt whenever the data changes.

High PE StocksStocks Under $100Stocks Under $50Mid Cap StocksDebt to Equity Below 1 StocksHigh Current Ratio Stocks

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.